Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma

A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral oncogene homolog ( ), neuroblastoma rat sarcoma viral oncogene homolog ( ) and v-raf murine sarcoma v...

Full description

Saved in:
Bibliographic Details
Published inExploration of targeted anti-tumor therapy Vol. 4; no. 2; pp. 307 - 315
Main Authors Lara-Morga, Celia, Palka-Kotlowska, Magda, Custodio-Cabello, Sara, Pacheco-Barcia, Vilma, Cabezón-Gutiérrez, Luis
Format Journal Article
LanguageEnglish
Published United States Open Exploration 2023
Open Exploration Publishing Inc
Subjects
Case Report
colorectal cancer
complete response
trifluridine/tipiracil (tas-102)
Complete response
colorectal cancer
trifluridine/tipiracil (TAS-102)
Online AccessGet full text

Cover

More Information
Summary:A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral oncogene homolog ( ), neuroblastoma rat sarcoma viral oncogene homolog ( ) and v-raf murine sarcoma viral oncogene homolog B ( ) wild-type, proficient mismatch repair (pMMR), in whom a complete response to the third-line of systemic treatment with trifluridine/tipiracil (TAS-102) was obtained. The complete response has been maintained for more than 2 years after its suspension.
ISSN:2692-3114
2692-3114
DOI:10.37349/etat.2023.00136